ADCT
Adc Therapeutics SA

1,254
Mkt Cap
$446.33M
Volume
555,938.00
52W High
$4.80
52W Low
$1.05
PE Ratio
-2.43
ADCT Fundamentals
Price
$3.53
Prev Close
$3.50
Open
$3.53
50D MA
$4.00
Beta
1.49
Avg. Volume
754,742.74
EPS (Annual)
-$1.62
P/B
-1.67
Rev/Employee
$267,309.43
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC...
PR Newswire·21h ago
News Placeholder
More News
News Placeholder
ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why
ADC Therapeutics (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·4d ago
News Placeholder
Corient Private Wealth LLC Makes New Investment in ADC Therapeutics SA $ADCT
Corient Private Wealth LLC purchased a new stake in ADC Therapeutics SA (NYSE:ADCT - Free Report) in the second quarter, according to the company in its most recent filing with the Securities...
MarketBeat·6d ago
News Placeholder
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines PR Newswire...
PR Newswire·14d ago
News Placeholder
ADC Therapeutics SA (NYSE:ADCT) Given Average Rating of "Moderate Buy" by Brokerages
ADC Therapeutics SA (NYSE:ADCT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six analysts that are currently covering the stock, Marketbeat reports. One analyst...
MarketBeat·14d ago
News Placeholder
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
Here is how ADC Therapeutics SA (ADCT) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Zacks·16d ago
News Placeholder
ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy?
Does ADC Therapeutics SA (ADCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·18d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC...
PR Newswire·22d ago
News Placeholder
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial PR Newswire LAUSANNE, Switzerland, Dec. 2, 2025 Company to host corporate...
PR Newswire·1mo ago
News Placeholder
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
Here is how ADC Therapeutics SA (ADCT) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Zacks·1mo ago
<
1
2
...
>

Latest ADCT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.